Piperacillin
- Generic Name
- Piperacillin
- Brand Names
- Pipracil, Zosyn
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N5O7S
- CAS Number
- 66258-76-2
- Unique Ingredient Identifier
- 9I628532GX
- Background
Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
- Indication
For the treatment of polymicrobial infections.
- Associated Conditions
- Animal bite, Bacterial Infections, Bone and Joint Infections, Community Acquired Pneumonia (CAP), Gynecological Infection, Infection, Mixed, Intraabdominal Infections, Lower Respiratory Tract Infection (LRTI), Nosocomial Pneumonia, Pelvic Infections, Septicemia, Skin and skin structure infections, Urinary Tract Infection, Uncomplicated Urethritis gonococcal caused by Neisseria Gonorrhoeae
- Associated Therapies
- -
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Phase 3
Completed
- Conditions
- Bacterial Pneumonia
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
Phase 3
Completed
- Conditions
- Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 398
- Registration Number
- NCT02473263
- Locations
- 🇫🇷
Anesthesiology, Intensive Care Unit and emergency department - Necker Hospital, Paris, France
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Not Applicable
- Conditions
- NeutropeniaHematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT01714557
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, Beijing, China
Study Evaluating BLI-489 and Piperacillin in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00894439
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath